Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Martinelli, Giovanni
Daver, Naval
Papayannidis, Cristina
Wei, Andrew http://orcid.org/0000-0002-7514-3298
Higgins, Brian
Ott, Marion
Mascarenhas, John http://orcid.org/0000-0002-8400-0483
Andreeff, Michael
Funding for this research was provided by:
Roche
Article History
Received: 28 April 2020
Revised: 11 June 2020
Accepted: 23 June 2020
First Online: 10 July 2020
Compliance with ethical standards
:
: MK has received research support and advisory or consultancy fees from Roche/Genentech and AbbVie. GM has no conflict of interests to disclose. ND has received grants and personal fees from Genentech, Pfizer, AbbVie, Astellas, Bristol Myers Squibb, Agios, Immunogen, Servier, and Daiichi Sankyo; grants from Novimmune; and personal fees from Jazz. CP has no conflict of interests to disclose. AW has received honoraria from and held consulting or advisory roles for Novartis, Astellas, Pfizer, MacroGenics, AbbVie, Genentech, Servier, Celgene, Amgen, AstraZeneca, and Janssen; been part of the speakers bureau for AbbVie, Genentech and Novartis; received research funding from Novartis, Celgene, AbbVie, Servier, AstraZeneca and Amgen; and is a former employee of the Walter and Eliza Hall Institute and receives a part of their royalty stream related to venetoclax. BH is a full-time employee of Roche and owns stock in the company. MO is a full-time employee of Roche and owns stock in the company. JM has received grants and personal fees from Roche, Incyte, Promedior, PharmaEssentia; grants from Kartos, Novartis, Merck, CTI Biopharma, and Janssen; and personal fees from Celgene and AbbVie. MA has received research support from Daiichi Sankyo.